Nintedanib (Ofev) for SSc-ILD: First Approved Antifibrotic
Nintedanib (Ofev, BI), triple TKI. SENSCIS Ph3 cut annual FVC decline 44% (NEJM 2019). FDA Sep 2019 first SSc-ILD approval. ATS / ACR-CHEST conditional.
Introduction: The First Antifibrotic for SSc-ILD
Before September 2019, systemic sclerosis-associated interstitial lung disease (SSc-ILD) — the leading cause of death in SSc — had no approved therapy. Cyclophosphamide and mycophenolate were used off-label. Boehringer Ingelheim's Nintedanib (Ofev), the triple TKI (PDGFR/FGFR/VEGFR) established in IPF, was extended to SSc-ILD on SENSCIS Phase 3 evidence showing a 44% relative reduction in annual FVC decline, earning the world-first SSc-ILD approval[1][2]. This article covers MoA differentiation, MMF combination strategy, and positioning vs Tocilizumab.
1. Compound Profile
| Item | Detail |
|---|---|
| Generic name | Nintedanib |
| Brand name | Ofev |
| Development code | BIBF 1120 |
| Sponsor | Boehringer Ingelheim |
| Modality | Oral small-molecule, triple TKI (PDGFR α/β, FGFR 1-3, VEGFR 1-3, Src, Lck) |
| Dose | 150 mg PO BID |
| SSc-ILD approvals | FDA 2019-09-06 (world-first, sNDA 205832/S-012)[1]; EMA SSc-ILD indication extension 2020-04[9]; PMDA 2019-12 (review document / prescribing information)[10] |
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. SSc-ILD Biology
- SSc is among the CTDs with the highest mortality; ILD is a leading cause of death (~35% of deaths per the ATS 2023 SSc-ILD guideline)[7]
- Mixed phenotype: immune-inflammatory (early dcSSc) → fibrotic (late)
- Prior SoC: CYC (SLS-I), MMF (SLS-II) — modest FVC preservation
- New axes: antifibrotic (Nintedanib) + immunomodulation (Tocilizumab, Rituximab)
3. Mechanism: Triple TKI in SSc-ILD
- PDGFR α/β: suppress fibroblast proliferation and myofibroblast differentiation
- FGFR 1-3: fibroblast signaling (preclinical models also suggest effects on vascular biology)
- VEGFR 1-3: suppress aberrant angiogenesis (capillary-dropout suppression observed in Fra2-Tg mice[5])
- TGF-β downstream: dampens via RTK crosstalk, not Smad
- Macrophage activation: suppressed (Fra2 model)
Compared to IPF (fibrosis-predominant), SSc-ILD has overlapping vascular injury, immune inflammation, and fibrosis, making broad TKI coverage a mechanistically interesting strategy — clinical superiority over single-target approaches has not been demonstrated in prospective comparative trials.
4. Clinical Evidence
4-1. SENSCIS Phase 3 (NCT02597933)[2]
- Design: 52-week RCT, n=576 (70 Japanese), Nintedanib 150 mg BID vs placebo
- Primary (annual FVC decline): −52.4 vs −93.3 mL/yr, between-group 41.0 mL/yr (95% CI 2.9–79.0, p=0.04, 44% relative reduction)
- MMF subgroup: consistent effect (PMID 33412120)
- Distler O et al., N Engl J Med 2019;380:2518-2528 (PMID 31112379)
4-2. SENSCIS-ON Extension
- Open-label; 3-year (148-wk) continued arm FVC −189.1 mL vs initiated −126.4 mL; safety consistent, diarrhea predominant
4-3. IPF (INPULSIS) and PF-ILD (INBUILD) Comparison
| Trial | Target | n | FVC slope |
|---|---|---|---|
| INPULSIS-1/2 (PMID 24836310) | IPF | 1066 | −114.7 vs −239.9 mL/yr |
| SENSCIS | SSc-ILD | 576 | −52.4 vs −93.3 mL/yr |
| INBUILD (PMID 31566307) | PF-ILD (incl. CTD-ILD ≠ SSc) | 663 | 57% reduction |
INBUILD drove 2020 FDA/EMA expansion to chronic fibrosing ILD with progressive phenotype.
5. Positioning in ATS 2023 SSc-ILD Guideline and ACR-CHEST SARD-ILD Guideline
The ATS 2023 SSc-ILD guideline[7] and the ACR/CHEST 2023 SARD-ILD guideline[6] are separate documents from separate societies with separate scopes, and their recommendation strengths must be cited separately.
ATS guideline (SSc-ILD focused):
- Mycophenolate: strong recommendation (first-line anti-inflammatory / antifibrotic)
- Cyclophosphamide / Rituximab: conditional recommendations
- Tocilizumab: conditional (early dcSSc with high inflammation)
- Nintedanib (monotherapy): conditional recommendation
- Nintedanib + Mycophenolate combination: conditional recommendation based on low-certainty evidence
ACR/CHEST guideline (SARD-ILD overall): covers systemic autoimmune rheumatic disease–associated ILDs more broadly, with conditional recommendations for nintedanib in progressive ILD subsets.
Evidence for Nintedanib + MMF combination: a systematic review/meta-analysis (Herman et al., PMID 37773000)[8] reported an additional ~80 mL/yr FVC preservation versus MMF alone, alongside an approximately 1.65-fold increase in SAEs. The certainty of evidence is low, and the guideline recommendation remains conditional.
Rapidly progressive cases: MMF + Tocilizumab + Nintedanib triple therapy has been explored in case reports and observational studies, but randomized evidence is limited and it is not a standard regimen.
6. Competitive Landscape
| Agent | MoA | SSc-ILD approval | Trial |
|---|---|---|---|
| Nintedanib | Triple TKI | FDA 2019-09 (world-first) | SENSCIS |
| Tocilizumab | anti-IL-6R | FDA 2021-03 | focuSSced |
| Rituximab | anti-CD20 | Off-label | DESIRES (Japan PMID 38279402), RECITAL |
| MMF | IMPDH inhibitor | Off-label | SLS-II |
7. Preclinical & Biomarkers
- Fra2-Tg mice: improves lung/skin fibrosis, PAH-like vasculopathy, capillary dropout; suppresses macrophage activation (Huang J et al., ARD 2017, PMID 28814429)
- Bleomycin osmotic-pump SSc-ILD: micro-CT confirms fibrosis suppression (Sci Rep 2021, PMID 34531421)
- Biomarkers: FVC slope, HRCT quantitation, KL-6, SP-D, CRP
Related: UUO renal fibrosis model, hydroxyproline assay for fibrosis endpoint alignment.
8. Points to Watch
- SENSCIS-ON long-term data >3 years
- MMF combination standardization — move beyond systematic review–level evidence to dedicated RCTs
- Tocilizumab combination — immune + fibrosis combination strategy without established standardized evidence
- Generics — as an oral small molecule, nintedanib is expected to face generic competition after patent expiry, affecting pricing
References
1. FDA. Drug Approval: Ofev (Nintedanib) for SSc-ILD, sNDA 205832/S-012, approved September 6, 2019. (FDA official URLs are unstable across site reorganizations; search Drugs@FDA for Application Number 205832. The 2019-09-06 approval is also cited by the ATS SSc-ILD guideline PMID 37772985.)
2. Distler O, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease (SENSCIS). N Engl J Med. 2019;380:2518-2528. PubMed 31112379 / ClinicalTrials.gov: NCT02597933
3. Flaherty KR, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (INBUILD). N Engl J Med. 2019;381:1718-1727. PubMed 31566307
4. Richeldi L, et al. Efficacy and Safety of Nintedanib in IPF (INPULSIS). N Engl J Med. 2014;370:2071-2082. PubMed 24836310
5. Huang J, et al. Nintedanib inhibits macrophage activation and inflammation in Fra2-Tg mice. Ann Rheum Dis. 2017. PubMed 28814429
6. Johnson SR, et al. 2023 ACR/CHEST Guideline for Treatment of Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken). 2024 Aug;76(8):1051-1069. PubMed 38973731
7. Raghu G, et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024 Jan;209(2):137-152. PubMed 37772985 (companion: Hossain T, et al. Ann Am Thorac Soc. 2024 Jan;21(1):12-16. PubMed 37856309 — clinician summary)
8. Herman D, et al. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis. Ann Am Thorac Soc. 2024 Mar;21(3):474-485. PubMed 37773000
9. European Medicines Agency. Ofev: EPAR — Product Information. EMA EPAR / EMA orphan designation (EU/3/16/1724)
10. PMDA Review Document (Ofev, nintedanib esylate, SSc-ILD indication extension December 2019). PMDA review document